MediciNova announces FDA granted orphan drug designation to MN-001 (tipelukast) for IPF
MediciNova announced the FDA has granted orphan-drug designation to MN-001 (tipelukast) for treatment of idiopathic pulmonary fibrosis. Orphan-drug designation will provide MediciNova with seven years of marketing exclusivity for MN-001 (tipelukast) for treatment of IPF if approved. October 22, 2014